Bush Jason R, Alfa Michelle J
MSP Starch Products Inc., Carberry, MB, Canada.
AlfaMed Consulting, Winnipeg, MB, Canada.
BMC Nutr. 2024 Nov 27;10(1):152. doi: 10.1186/s40795-024-00962-7.
Studies have linked a lack of dietary fibre, including resistant starch (RS), to disease-associated changes in intestinal bacteria. Healthy people often report abnormal bowel symptoms (ABS), including bloating, constipation, abdominal pain, and diarrhea, however, connections between these symptoms and the gut microbiota are poorly understood. Determining correlations between ABS and taxonomic groups may provide predictive value for using prebiotics to mitigate ABS in combination with stool microbiome testing.
Post hoc analysis of a three-arm randomized, double-blind, placebo-controlled clinical trial evaluating the effects of 3.5 g and 7 g resistant potato starch (RPS) doses or placebo was conducted. The study population (n = 70) were healthy adults aged 18-69 years old living in and around Guelph, ON. Participants evaluated their stools using the Bristol Stool Chart and also recorded any ABS daily. The presence of ABS was compared between treatment arms at baseline and changes in ABS were compared within treatment arms over 1- and 4-week periods. Pearson correlation analysis was used to identify significant relationships between changes in ABS and changes in bacterial taxa.
Abdominal pain, belching, bloating, constipation, diarrhea, gas, and feeling unwell were reported by participants at low levels at baseline. Neither RPS nor placebo had significant effects on mean ABS scores. However, we identified positive correlations between treatment-dependent changes in symptoms and changes in Granulicatella, Haemophilus, Lachnospira, Olsenella, Papillibacter, Turicibacter, unclassified Enterobacteriaceae, unclassified Fusobacteriaceae, unclassified Pasteurellaceae, and unclassified Gammaproteobacteria. We also identified negative correlations between treatment-dependent changes in symptoms and changes in Anaerotruncus, Dorea, RFN20, Victivallis, unclassified Coriobacteriaceae, and unclassified Oxalobacteraceae. These Pearson correlations were significant after correction for repeated testing. The mean relative abundance of these taxa did not change in response to treatment. Finally, macronutrient intake was unaffected by RPS or placebo treatments.
Changes in ABS can be positively or negatively correlated with changes in specific gut microbiota, creating opportunities for personalized microbiome-targeted interventions to resolve ABS.
The trial was registered at ClinicalTrials.gov (NCT05242913) on February 16, 2022.
研究表明，缺乏膳食纤维，包括抗性淀粉（RS），与肠道细菌的疾病相关变化有关。健康人常报告肠道异常症状（ABS），包括腹胀、便秘、腹痛和腹泻，然而，这些症状与肠道微生物群之间的联系尚不清楚。确定ABS与分类菌群之间的相关性，可能为使用益生元结合粪便微生物组检测来减轻ABS提供预测价值。
对一项三臂随机、双盲、安慰剂对照临床试验进行事后分析，该试验评估了3.5克和7克抗性马铃薯淀粉（RPS）剂量或安慰剂的效果。研究人群（n = 70）为居住在安大略省圭尔夫市及其周边地区的18 - 69岁健康成年人。参与者使用布里斯托大便分类法评估他们的粪便，并每天记录任何ABS。在基线时比较各治疗组之间ABS的存在情况，并在1周和4周期间比较各治疗组内ABS的变化。使用Pearson相关分析来确定ABS变化与细菌分类群变化之间的显著关系。
参与者在基线时报告的腹痛、嗳气、腹胀、便秘、腹泻、气体和不适等症状水平较低。RPS和安慰剂对平均ABS评分均无显著影响。然而，我们发现症状的治疗依赖性变化与颗粒链菌属、嗜血杆菌属、毛螺菌属、奥尔森菌属、乳头杆菌属、Turicibacter、未分类的肠杆菌科、未分类的梭杆菌科、未分类的巴斯德菌科和未分类的γ-变形菌纲的变化之间存在正相关。我们还发现症状的治疗依赖性变化与厌氧短杆菌属、多雷亚菌属、RFN20、Victivallis、未分类的棒状杆菌科和未分类的草酸杆菌科的变化之间存在负相关。在对重复测试进行校正后，这些Pearson相关性具有显著性。这些分类群的平均相对丰度在治疗后没有变化。最后，宏量营养素的摄入不受RPS或安慰剂治疗的影响。
ABS的变化可能与特定肠道微生物群的变化呈正相关或负相关，这为个性化的针对微生物组的干预措施来解决ABS创造了机会。
该试验于2022年2月16日在ClinicalTrials.gov（NCT05242913）注册。
